Hyperlipidemia is a significant risk factor for cardiovascular disease morbidity and mortality. The lipid-lowering drugs are considered the cornerstone of primary and secondary prevention of atherosclerotic cardiovascular disease. Unfortunately, the lack of efficacy and associated adverse effects, ranging from mild-to-moderate to potentially life-threatening, lead to therapy discontinuation. Numerous reports support the role of gene polymorphisms in drugs' pharmacokinetic parameters and their associated adverse reactions. Therefore, this study aims to understand the pharmacogenomics of lipid-lowering drugs and the impact of genetic variants of key genes on the drugs' efficacy and toxicity. Indeed, genetically guided lipid-lowering therapy enhances overall safety, improves drug adherence and achieves long-term therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/pme-2022-0041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GWAS of CRP response to statins further supports the role of APOE in Statin Response: a GIST consortium study.
Pharmacol Res
January 2025
Centre of Clinical Pharmacology & Precision Medicine, William Harvey Research Institute, Queen Mary University of London, London, UK; NIHR Barts Biomedical Research Centre, Queen Mary University of London, London, UK. Electronic address:
Article Synopsis
- Statins are key medications used to prevent cardiovascular disease by not only lowering lipids but also reducing inflammation, measured by C-reactive protein (CRP).
- Two significant genetic loci linked to how individuals respond to statin treatment in terms of changes in CRP levels were identified: APOE and HNF1A, both of which are associated with various health conditions like coronary artery disease and diabetes.
- Further analysis suggests that the APOE-E4 variant may influence the effectiveness of statins, hinting at its potential role in personalized healthcare for those with cardiovascular and related conditions.
A Study Of the effect of Sex on drug dosing, concentrations, and pharmacogenomics in the Montreal Heart Institute Hospital Cohort (SOS-PGx): methodology and research progress.
Eur J Clin Pharmacol
February 2025
Faculty of Pharmacy, Université de Montréal, 2940 Chemin de Polytechnique, Montreal, Quebec, H3T 1J4, Canada.
Background: Women are underrepresented in drug development trials and there is no sex-tailored drug regimen for most medications. It has been repeatedly shown that women have more adverse drug reactions than men for several medications. These differences could be explained by higher dose-adjusted drug concentrations in women.
View Article and Find Full Text PDFAssociations Between Gene Variants of Lipid-Lowering Drug Targets and Adverse Outcomes After Ischemic Stroke.
J Am Heart Assoc
November 2024
Article Synopsis
- The study investigates how genetic variations in lipid-lowering drug targets relate to the prognosis of ischemic stroke patients, highlighting a previously unclear area.
- It identifies specific gene variants (rs2006760-C, rs11206510-T, rs1864163-G, and rs9929488-G) that are linked to a higher likelihood of death or major disability within two years after a stroke.
- The research concludes that a higher genetic risk score, calculated from these variants, is associated with an increased risk of adverse outcomes, making it a potential predictor for stroke prognosis.
Utility of a Systolic Blood Pressure Polygenic Risk Score With Chlorthalidone Response.
JAMA Cardiol
December 2024
Department of Epidemiology, University of Alabama at Birmingham.
Article Synopsis
- A study investigated how well a polygenic risk score (PRS) for systolic blood pressure (SBP) can predict patients' responses to antihypertensive treatment and the risk of treatment-resistant hypertension.
- The research focused on participants from the GenHAT study, specifically Black individuals who were assigned to treatment groups involving chlorthalidone or lisinopril.
- The main outcomes measured were changes in blood pressure after six months and the likelihood of being classified as treatment-resistant hypertension based on defined criteria.
Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic.
Eur Heart J Cardiovasc Pharmacother
October 2024
Editor-in-Chief.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!